HONG KONG, 3 September 2026 – HUTCHMED (China) Limited has signed a definitive agreement with a subsidiary of GSK plc that provides the UK pharmaceutical group with exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
Under the terms, HUTCHMED will receive an upfront payment of US$110.00 million and is eligible for development, regulatory and commercial milestones of up to US$1.19 billion, bringing the potential transaction value to US$1.30 billion. In addition, tiered royalties will be paid on net sales generated by GSK in its licensed territories. Closing is subject to customary conditions, including antitrust clearance.
HUTCHMED will conduct the global Phase I study, expected to start in 2H 2026 (clinicaltrials.gov ID: NCT07718581). GSK will assume all subsequent development and commercial responsibilities in its territories. HUTCHMED retains full commercial rights in Mainland China, Hong Kong, Macau and Taiwan. The agreement also grants GSK a right of first negotiation for one earlier-stage ATTC candidate from HUTCHMED’s pipeline.
HMPL-A830 combines a potent, highly selective KRAS inhibitor payload with an anti-EGFR antibody, designed to deliver dual blockade of KRAS and EGFR signalling while concentrating cytotoxic activity within EGFR-expressing tumours. Initial clinical focus areas include colorectal cancer (KRAS mutations in ~44 % of patients), lung adenocarcinoma (~34 %) and pancreatic ductal adenocarcinoma (up to ~89 %). By uniting targeted antibody delivery with small-molecule inhibition, the ATTC aims to overcome resistance mechanisms and systemic toxicity that limit current KRAS-directed therapies.
The collaboration marks the first global out-licensing of a drug candidate from HUTCHMED’s ATTC platform and its third programme based on proprietary small-molecule payloads. Bank of America Securities acted as exclusive financial adviser to HUTCHMED.
Management from both companies highlighted the potential for HMPL-A830 to improve outcomes in tumour types with high unmet KRAS-driven disease burden and signalled a shared commitment to accelerating development through the planned Phase I trial and beyond.